Peter Kaiser, the Chief Development Officer of $OCUL, sold 3,035 shares of the company on 08-24-2026 for an estimated $32,686. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.1% of their shares of this class of stock. Following this trade, they now own 264,378 shares of this class of $OCUL stock.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 42,805 shares for an estimated $406,638.
- NADIA WAHEED (Chief Medical Officer) sold 14,828 shares for an estimated $122,627
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 2 sales selling 6,314 shares for an estimated $60,278.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 2 sales selling 6,002 shares for an estimated $57,016.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,755 shares for an estimated $35,685.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OCUL Hedge Fund Activity
We have seen 136 institutional investors add shares of $OCUL stock to their portfolio, and 155 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 3,902,667 shares (-94.5%) from their portfolio in Q2 2026, for an estimated $38,324,189
- BLACKROCK, INC. added 3,243,624 shares (+20.1%) to their portfolio in Q2 2026, for an estimated $31,852,387
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,935,284 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $24,861,855
- COMMODORE CAPITAL LP removed 2,575,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $25,286,500
- DELTEC ASSET MANAGEMENT LLC removed 2,340,620 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,984,888
- POINT72 ASSET MANAGEMENT, L.P. removed 2,242,792 shares (-40.5%) from their portfolio in Q2 2026, for an estimated $22,024,217
- DIMENSIONAL FUND ADVISORS LP added 2,133,611 shares (+328.4%) to their portfolio in Q2 2026, for an estimated $20,952,060
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OCUL Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Clear Street issued a "Buy" rating on 03/03/2026
To track analyst ratings and price targets for $OCUL, check out Quiver Quantitative's $OCUL forecast page.
$OCUL Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 6 analysts offer price targets for $OCUL in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Andreas Argyrides from Chardan Capital set a target price of $23.0 on 06/25/2026
- Colleen Kusy from Baird set a target price of $30.0 on 06/18/2026
- Yi Chen from HC Wainwright & Co. set a target price of $25.0 on 06/18/2026
- Lisa Walter from RBC Capital set a target price of $30.0 on 05/06/2026
- Serge Belanger from Needham set a target price of $18.0 on 05/05/2026
- Bill Maughan from Clear Street set a target price of $28.0 on 03/03/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
